Singapore, March 22 -- 60 Degrees Pharmaceuticals (60P) and its Australian distribution partner Biocelect Pty Ltd, began commercialising the new malaria prevention medicine, Kodatef(R) (tafenoquine succinate). The two organisations announced that the first shipments of Kodatef have arrived and are now available to customers in Australia.

In September 2018, the Therapeutic Goods Administration (TGA) approved Kodatef for the prevention of malaria in adults 18 years of age and above for up to 6 months of continuous dosing. The approval marked the first time in more than 20 years that the TGA had approved a new drug for the prevention of malaria. Malaria remains widespread in many countries, including Australia's near neighbors.

Doug Loock,...